ORIC Pharmaceuticals Highlights Rinzimetostat's Resistance-Busting Potential in Prostate Cancer
Event summary
- ORIC Pharmaceuticals will present preclinical data on rinzimetostat (ORIC-944) at the 2026 AACR Annual Meeting, April 17-22.
- Rinzimetostat demonstrated superior inhibition of PRC2 complexes in prostate cancer models resistant to EZH2 inhibitors.
- Phase 1b trial of rinzimetostat in combination with AR inhibitors is ongoing in metastatic prostate cancer (NCT05413421).
- Transcriptome analysis of 1,000+ prostate cancer samples supports PRC2 inhibition as a strategy to overcome AR pathway resistance.
The big picture
ORIC's data suggests a potential paradigm shift in treating prostate cancer by targeting PRC2 resistance mechanisms. The focus on combination therapies aligns with broader oncology trends toward overcoming treatment resistance through epigenetic modulation. Success here could position rinzimetostat as a key player in the evolving prostate cancer treatment landscape.
What we're watching
- Clinical Validation
- Whether rinzimetostat's preclinical advantages in resistance settings translate to improved outcomes in the ongoing phase 1b trial.
- Competitive Positioning
- How ORIC positions rinzimetostat against existing EZH2 inhibitors like tazemetostat in the prostate cancer market.
- Regulatory Pathway
- The pace at which ORIC advances rinzimetostat through clinical development given the complexity of combination therapies.
Related topics